Suchergebnisse - "Gulick, Roy M"

PubPharm (263)

41

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

enthalten in: Nature medicine | 2018

von Bar-On, Y. | Gruell, H. | Schoofs, T. | +30

CommentIn: Nature. 2018 Sep;561(7724):468-470. - PMID 30258147

42

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study : Posttreatment Controllers Identified From 14 Clinical Studies

enthalten in: The Journal of infectious diseases | 2018

von Namazi, G. | Fajnzylber, J. | Aga, E. | +29

43

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

enthalten in: Nature | 2018

von Mendoza, P. | Gruell, H. | Nogueira, L. | +33

CommentIn: Nature. 2018 Sep;561(7724):468-470. - PMID 30258147

44

Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117

enthalten in: The Journal of experimental medicine | 2018

von Cohen, Y. | Lorenzi, J. | Krassnig, L. | +18

45

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events

enthalten in: Pharmacogenetics and genomics | 2018

von Haas, D. | Bradford, Y. | Verma, A. | +9

46

New HIV drugs : 2018 and beyond

enthalten in: Current opinion in HIV and AIDS | 2018

von Gulick, R.

47

Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells

enthalten in: AIDS research and human retroviruses | 2018

von Figueroa, D. | Madeen, E. | Tillotson, J. | +10

48

ACTG A5353 : A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2018

von Taiwo, B. | Zheng, L. | Stefanescu, A. | +11

49

Investigational Antiretroviral Drugs : What is Coming Down the Pipeline

enthalten in: Topics in antiviral medicine | 2018

von Gulick, R.

50

No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP) : Findings from HPTN 069/ACTG A5305

enthalten in: PloS one | 2018

von Kapadia, S. | Wu, C. | Mayer, K. | +9